have identified CHRDL1, NEFH, TAGLN, and SYNM as novel diagnostic biomarkers for BPH and PCa, which aid in early diagnosis, treatment, and assessment of immunotherapeutic responses. The gene discussed is TAGLN; the disease is posterior cortical atrophy.